3H Pharma initiates the first-in-human study of 3HP-2827 in patients with solid tumors with FGFR2 alterations
3H (Suzhou) Pharmaceuticals (思康睿奇药业) commences its first-in-human study ( NCT06287918 ) of 3HP-2827, an FGFR2 inhibitor, in patients with solid tumors exhibiting FGFR2 alterations in the United States. The clinical trial aims to enroll an estimated 130 participants. 3HP-2827 The Investigational New Drug (IND) application was submitted to the China Center for Drug Evaluation (CDE) on December 30, 2023. The IND has been approved for use either as monotherapy or in combination with chemotherapy or immunotherapy in patients with advanced cancers. Additional IND applications will be filed in East Asian countries. The FGFR2 belongs to the FGFR family of tyrosine kinase receptors. The family consists of 4 genes that encode single-pass transmembrane receptors that bind to FGF on the extracellular domain. Ligand binding trigger a signaling cascade that may exercise several cellular functions, including cell survival. It is estimated that FGFR2 genomic alterations are present in around 10-15%